THE ECONOMIC BURDEN OF TREATING THALASSEMIA IN GREECE
Author(s)
Geitona M1, Karagianni V2, Kattamis A3, Voskaridou E4, Drosou M5, Vini D5, Kalogeropoulou M6
1University of Peloponnese, Corinth, Greece, 2Technological educational institute of Athens, Egaleo, Greece, 3Ag. Sofia Children Hospital, Goudi, Greece, 4Laiko General Hospital of Athens, Ambelokipi, Greece, 5Agios Panteleimon General Hospital, Nikaia, Greece, 6Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece
OBJECTIVES The objective was to estimate the economic burden of B-thalassemia and to compare the cost of alternative iron chelation strategies in patients with transfusion (TDT) and non-transfusion dependent thalassemias (NTDT) in Greece. METHODS A multicenter, non interventional, retrospective, observational, phase IV study was conducted in the 3 out of 8 thalassemia units in Attica. Patients’ data and resource use, including medication and related consumables, blood transfusions, lab tests, diagnostic examinations and hospital visits were recorded from January 2009 to December 2011, and classified per diagnosis and iron chelation treatment strategies. Greek NHS perspective was considered. RESULTS
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PSY31
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Systemic Disorders/Conditions